Novel PCR-based mRNA drug substance manufacturing enhancing our integrated mRNA CDMO offering
（和訳：「独自のPCR法をベースとしたmRNA原薬製造と強化されたmRNA CDMOサービス」）

発表要旨

mRNA-therapeutics have become the most widely known and growing modality in recent years. While COVID vaccine development occurred in record time, manufacturing technologies are critical for developing new mRNA applications. This presentation covers how our unique PCR-based mRNA production technology can accelerate mRNA development & manufacturing, enhancing the benefits of our integrated CDMO offering including Lipids, LNP formulation and final fill & finish.

プロフィール

Julian is the strategic marketing manager for mRNA solutions and responsible for the strategy development and positioning of the mRNA CDMO offering based on the acquisition of AmpTec GmbH, a leading mRNA CDMO. Prior to joining Merck KGaA in Darmstadt, Germany, he gained experience in translational research with profound expertise in the areas of novel modalities and in vivo gene editing. Julian holds a M.Sc. in bioprocess development and a Ph.D. in translational immunology from Heidelberg University.